Tradestie Institutional Equity Comparison Engine
COCP vs IBIO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
IBIO Overall Edge
IBIO Captures Institutional Edge (1โ1 Pillars ยท 4โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to iBio, Inc. Common Stock (IBIO) driven by superior Growth & Margin while COCP counters with relative strength in Momentum & Technical. Fundamentally, COCP trades at N/M Forward P/E with -3063.6% operating margin (+26.9% YoY revenue) versus IBIO at N/M Forward P/E and -3025.6% operating margin (+975.0% YoY). In options structure, COCP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against IBIO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
COCP N/M vs IBIO N/M Fwd P/E
Growth & Margin Winner
IBIO
Op Margin -3063.6% vs -3025.6% ยท YoY +26.9% vs +975.0%
Momentum & Technical Winner
COCP
1Y -3.0% vs -37.7% ยท 52W Pos 19% vs 1%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
COCP
NASDAQ
Cocrystal Pharma, Inc. Common Stock
Pharmaceutical Preparations
$1.00
+1.98% 1D
Market Cap
$19.6M
1M Return
-2.01%
1Y Return
-2.96%
Forward P/E
N/M
Unified AI Score
47.1 / 100
HOLD
Tech 51.0
Fund 48.0
Flow 50.0
Mom 54.0
IBIO
NASDAQ
iBio, Inc. Common Stock
Pharmaceutical Preparations
$0.72
-2.04% 1D
Market Cap
$53.7M
1M Return
-6.46%
1Y Return
-37.67%
Forward P/E
N/M
Unified AI Score
46.0 / 100
HOLD
Tech 45.0
Fund 46.0
Flow 50.0
Mom 64.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
COCP -2.96%
IBIO -37.67%
Spread: +34.71 pp (COCP Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | COCP Revenue | IBIO Revenue | COCP Op. Margin | IBIO Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | N/A | $0M | N/A | -3204.3% | IBIO |
| FY2019 | $10M | $0M | -737.4% | -782.4% | COCP |
| FY2020 | $0M | $0M | -476.0% | -854.9% | COCP |
| FY2021 | N/A | $0M | N/A | -1312.1% | IBIO |
| FY2022 | N/A | $0M | N/A | -1576.3% | IBIO |
| FY2024 | N/A | $0M | N/A | -7392.9% | IBIO |
| FY2025 | N/A | $0M | N/A | -4650.5% | IBIO |
| FY2026 | N/A | $0M | N/A | -35141.0% | IBIO |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | COCP | IBIO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $19.6M | $53.7M | Larger Scale | IBIO |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +26.9% | +975.0% | Higher Growth | IBIO |
| Operating Margin (TTM) Profitability | -3063.6% | -3025.6% | Higher Margin | IBIO |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -311.7% | -51.8% | Higher ROE | IBIO |
| 52-Week Range Position Momentum | 19% ($1โ$2) | 1% ($1โ$4) | Stronger Trend | COCP |
| Beta / 30D Volatility Risk Regime | 1.04ฮฒ ยท 54% Vol | 2.07ฮฒ ยท 89% Vol | Lower Realized Risk | COCP |
| Unified Institutional Score Composite Signal | 47.1 / 100 (HOLD) | 46.0 / 100 (HOLD) | Higher Composite | COCP |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full COCP vs IBIO Buy Guide
COCP
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
IBIO
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither COCP nor IBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.